3. Eli Lilly and Company (NYSE:LLY)
Market Cap $1,183.36 billion | Beta 0.43 | Net Profit Margin 33.53%
Diabetes and Weight-Loss Demand Drive a Sharp Revenue Increase
Eli Lilly and Company (NYSE: LLY) brings the strongest supplied net profit margin in this healthcare stocks selection, alongside substantial operating momentum. Second-quarter 2026 revenue increased 48% to approximately $23 billion, driven primarily by higher Mounjaro and Zepbound volumes.
The distinction between volume and pricing matters. Worldwide volume increased 60%, while realized prices declined 13%. Revenue growth therefore came from a substantial expansion in demand rather than higher prices alone. That is a powerful commercial signal, although it also highlights the importance of maintaining production capacity and patient access.
Reported earnings per share increased 26% to $7.94. Management raised full-year revenue guidance to between $85 billion and $87 billion. However, acquired research and development charges more than offset an increase in underlying adjusted earnings guidance, leaving the updated full-year adjusted EPS range at $35.50 to $36.50.
The pipeline adds another potential growth avenue. The company reported positive results from three additional Phase 3 retatrutide trials in obesity and outlined plans for a U.S. regulatory submission in the first quarter of 2027. Those plans represent a development opportunity rather than an approved source of future revenue.
For investors researching weight-loss drug stocks and diabetes treatments, the growth case is clear. The remaining question is how much future success the share price already reflects. A market capitalization exceeding $1 trillion makes valuation discipline particularly relevant.
Ranking Rationale
Eli Lilly and Company (NYSE: LLY) holds third place in the supplied order, with beta of 0.43 and net profit margin of 33.53%. Its profitability leads this group, but profitability is a screening requirement rather than the primary ranking measure. The third-place position should not be interpreted as evidence that it offers the third-best valuation or expected return.
